CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?

OncoImmunology

Volumn 3, Issue 5, 2014, Pages

  Tettamanti, Sarah ^a   Biondi, Andrea ^a   Biagi, Ettore ^a   Bonnet, Dominique ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

AML; Anti CD123; CAR T cells; Immunotherapy; Leukemic stem cells

Indexed keywords

CD123 ANTIGEN; CD33 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; IMMUNOTOXIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CYTOKINE INDUCED KILLER T CELL; CYTOKINE RELEASE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA CELL; NONHUMAN; T LYMPHOCYTE;

EID: 84904052509     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28835     Document Type: Article

References (11)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
2. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25:1315-21; PMID:17952057; http://dx.doi.org/10.1038/nbt1350
3. Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104:1442-52; PMID:16116598; http://dx.doi.org/10.1002/cncr.21326
4. Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010; 95:2144-52; PMID:20713459; http://dx.doi.org/10.3324/haematol.2010.026310
5. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14:1777-84; PMID:11021753; http://dx.doi.org/10.1038/sj.leu.2401903
6. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007; 92:952-9; PMID:17606446; http://dx.doi.org/10.3324/haematol.11132
7. Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, Maltese F, Galimberti S, Lopez AF, Biondi A, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013; 161:389-401; PMID:23432359; http://dx.doi.org/10.1111/bjh.12282
8. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134
9. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptormodified T cells. Blood. Blood 2014; (Forthcoming); http://dx.doi.org/10.1182/blood-2013-09-529537
10. Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E, Pule M. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods 2012; 23:376-86; PMID:23186165; http://dx.doi.org/10.1089/hgtb.2012.050
11. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, Biondi A, Biagi E, Bonnet D. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014; [Forthcoming]. PMID:24504024; http://dx.doi.org/10.1038/leu.2014.62